Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer

NCT03046862 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Neoplasms

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab
DRUG: Gemcitabine
DRUG: Cisplatin

Sponsor

Seoul National University Hospital